BRPI1005702B1 - método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto - Google Patents

método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto Download PDF

Info

Publication number: BRPI1005702B1
Authority: BR; Brazil
Prior art keywords: embryo; derivatives; galectin; galactoside; beta
Prior art date: 2010-12-21

Application number

BRPI1005702A

Other languages

English (en)

Portuguese (pt)

Inventor

Del Cistia Andrade Camillo

Da Silva Carvalho Morani Erika

Cataldi Rodrigues Lílian

Dias Baruffi Marcelo

Roncoletta Marcelo

Original Assignee

Inprenha Biotecnologia E Desenvolvimento Avancado Ltda Me

Univ Sao Paulo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-21

Filing date

2010-12-21

Publication date

2020-02-04

2010-12-21 Application filed by Inprenha Biotecnologia E Desenvolvimento Avancado Ltda Me, Univ Sao Paulo filed Critical Inprenha Biotecnologia E Desenvolvimento Avancado Ltda Me

2010-12-21 Priority to BRPI1005702A priority Critical patent/BRPI1005702B1/pt

2011-12-09 Priority to CN201180068131.8A priority patent/CN103702720B/zh

2011-12-09 Priority to JP2013544976A priority patent/JP6120374B2/ja

2011-12-09 Priority to PCT/BR2011/000454 priority patent/WO2012083396A1/en

2011-12-09 Priority to PL11805370T priority patent/PL2654897T3/pl

2011-12-09 Priority to RU2013133832A priority patent/RU2631598C2/ru

2011-12-09 Priority to ES11805370T priority patent/ES2756773T3/es

2011-12-09 Priority to EP11805370.1A priority patent/EP2654897B1/en

2011-12-09 Priority to CN201811493360.4A priority patent/CN109966474A/zh

2011-12-09 Priority to US13/996,920 priority patent/US9637533B2/en

2011-12-09 Priority to PT118053701T priority patent/PT2654897T/pt

2011-12-09 Priority to EP19189687.7A priority patent/EP3623008A1/en

2013-04-02 Publication of BRPI1005702A2 publication Critical patent/BRPI1005702A2/pt

2013-06-21 Priority to ZA2013/04626A priority patent/ZA201304626B/en

2017-01-05 Priority to JP2017000467A priority patent/JP2017081976A/ja

2018-10-01 Priority to JP2018186468A priority patent/JP6673998B2/ja

2020-02-04 Publication of BRPI1005702B1 publication Critical patent/BRPI1005702B1/pt

Links

210000004291 uterus Anatomy 0.000 title claims abstract description 77
238000000034 method Methods 0.000 title claims abstract description 74
102000007563 Galectins Human genes 0.000 title claims abstract description 65
108010046569 Galectins Proteins 0.000 title claims abstract description 65
230000008774 maternal effect Effects 0.000 title claims abstract description 56
241000124008 Mammalia Species 0.000 title claims abstract description 44
230000032692 embryo implantation Effects 0.000 title claims abstract description 17
102000004856 Lectins Human genes 0.000 claims abstract description 20
108090001090 Lectins Proteins 0.000 claims abstract description 20
239000002523 lectin Substances 0.000 claims abstract description 20
108010001498 Galectin 1 Proteins 0.000 claims description 76
102000000795 Galectin 1 Human genes 0.000 claims description 75
210000001161 mammalian embryo Anatomy 0.000 claims description 59
210000000582 semen Anatomy 0.000 claims description 28
210000000287 oocyte Anatomy 0.000 claims description 27
238000012423 maintenance Methods 0.000 claims description 21
238000000338 in vitro Methods 0.000 claims description 17
230000004720 fertilization Effects 0.000 claims description 14
239000000243 solution Substances 0.000 claims description 12
238000012546 transfer Methods 0.000 claims description 12
102100031351 Galectin-9 Human genes 0.000 claims description 5
101710121810 Galectin-9 Proteins 0.000 claims description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
108010001517 Galectin 3 Proteins 0.000 claims description 4
102000000802 Galectin 3 Human genes 0.000 claims description 4
102000044513 Galectin-13 Human genes 0.000 claims description 4
101000620927 Homo sapiens Galactoside-binding soluble lectin 13 Proteins 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 4
239000007853 buffer solution Substances 0.000 claims description 4
239000002953 phosphate buffered saline Substances 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
230000009261 transgenic effect Effects 0.000 claims description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
150000008195 galaktosides Chemical class 0.000 claims 2
239000011230 binding agent Substances 0.000 claims 1
210000002257 embryonic structure Anatomy 0.000 description 56
238000002513 implantation Methods 0.000 description 39
108090000623 proteins and genes Proteins 0.000 description 26
102000004169 proteins and genes Human genes 0.000 description 25
230000035935 pregnancy Effects 0.000 description 19
241000283690 Bos taurus Species 0.000 description 18
230000001850 reproductive effect Effects 0.000 description 18
238000004519 manufacturing process Methods 0.000 description 17
239000002609 medium Substances 0.000 description 16
241000894007 species Species 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
210000004696 endometrium Anatomy 0.000 description 12
238000002360 preparation method Methods 0.000 description 11
230000008569 process Effects 0.000 description 11
239000000047 product Substances 0.000 description 11
235000014676 Phragmites communis Nutrition 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
239000002158 endotoxin Substances 0.000 description 10
230000014509 gene expression Effects 0.000 description 10
244000144980 herd Species 0.000 description 9
239000008101 lactose Substances 0.000 description 9
210000002459 blastocyst Anatomy 0.000 description 8
238000009395 breeding Methods 0.000 description 8
230000001488 breeding effect Effects 0.000 description 8
238000011282 treatment Methods 0.000 description 8
230000000961 alloantigen Effects 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
230000012010 growth Effects 0.000 description 7
230000006872 improvement Effects 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
108700027921 interferon tau Proteins 0.000 description 7
230000009467 reduction Effects 0.000 description 7
230000000694 effects Effects 0.000 description 6
230000008014 freezing Effects 0.000 description 6
238000007710 freezing Methods 0.000 description 6
230000006870 function Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000009027 insemination Effects 0.000 description 6
229920006008 lipopolysaccharide Polymers 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
241001494479 Pecora Species 0.000 description 5
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 5
210000004246 corpus luteum Anatomy 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
230000012173 estrus Effects 0.000 description 5
230000035558 fertility Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 5
239000000463 material Substances 0.000 description 5
235000013336 milk Nutrition 0.000 description 5
239000008267 milk Substances 0.000 description 5
210000004080 milk Anatomy 0.000 description 5
230000004044 response Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
241000283707 Capra Species 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
239000008366 buffered solution Substances 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
238000003307 slaughter Methods 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
101150029062 15 gene Proteins 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
102000004264 Osteopontin Human genes 0.000 description 3
108010081689 Osteopontin Proteins 0.000 description 3
241000282898 Sus scrofa Species 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
235000015278 beef Nutrition 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000021164 cell adhesion Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000008021 deposition Effects 0.000 description 3
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
231100000562 fetal loss Toxicity 0.000 description 3
210000003754 fetus Anatomy 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000006058 immune tolerance Effects 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000000472 morula Anatomy 0.000 description 3
230000016087 ovulation Effects 0.000 description 3
230000008775 paternal effect Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
210000002826 placenta Anatomy 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
238000004321 preservation Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000004611 spectroscopical analysis Methods 0.000 description 3
239000010902 straw Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
210000002993 trophoblast Anatomy 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
206010055690 Foetal death Diseases 0.000 description 2
101001042451 Homo sapiens Galectin-1 Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000019802 Sexually transmitted disease Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000008512 biological response Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000005138 cryopreservation Methods 0.000 description 2
235000021051 daily weight gain Nutrition 0.000 description 2
235000013365 dairy product Nutrition 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
230000002357 endometrial effect Effects 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
238000002270 exclusion chromatography Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
230000003067 hemagglutinative effect Effects 0.000 description 2
102000045521 human LGALS1 Human genes 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
230000004957 immunoregulator effect Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000003447 ipsilateral effect Effects 0.000 description 2
230000001866 lectinic effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
244000144972 livestock Species 0.000 description 2
230000029860 luteolysis Effects 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
230000013011 mating Effects 0.000 description 2
230000035800 maturation Effects 0.000 description 2
235000013372 meat Nutrition 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000035882 stress Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000010257 thawing Methods 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
230000035899 viability Effects 0.000 description 2
238000004017 vitrification Methods 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000289695 Eutheria Species 0.000 description 1
241000282324 Felis Species 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
238000011050 LAL assay Methods 0.000 description 1
101710197063 Lectin-3 Proteins 0.000 description 1
239000006137 Luria-Bertani broth Substances 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000282849 Ruminantia Species 0.000 description 1
206010042573 Superovulation Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000003975 animal breeding Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
230000034196 cell chemotaxis Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000027326 copulation Effects 0.000 description 1
239000002577 cryoprotective agent Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000010612 desalination reaction Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000026826 estrous cycle phase Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
210000004996 female reproductive system Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
210000001650 focal adhesion Anatomy 0.000 description 1
230000003325 follicular Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
231100001039 immunological change Toxicity 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000009200 mechanosensation Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000002394 ovarian follicle Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920000024 polymyxin B Polymers 0.000 description 1
229960005266 polymyxin b Drugs 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000037195 reproductive physiology Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000010187 selection method Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008010 sperm capacitation Effects 0.000 description 1
238000012414 sterilization procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
230000003614 tolerogenic effect Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1732—Lectins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4726—Lectins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Marine Sciences & Fisheries (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

BRPI1005702A 2010-12-21 2010-12-21 método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto BRPI1005702B1 (pt)

Priority Applications (15)

Application Number	Priority Date	Filing Date	Title
BRPI1005702A BRPI1005702B1 (pt)	2010-12-21	2010-12-21	método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto
EP11805370.1A EP2654897B1 (en)	2010-12-21	2011-12-09	Method for increasing embryo implantation rate in mother's uterus in mammals, use of an effective amount of beta-galactoside-binding lectin or derivatives thereof, beta-galactoside-binding lectin or derivatives and product
CN201811493360.4A CN109966474A (zh)	2010-12-21	2011-12-09	用于在哺乳动物中增加母体子宫的胚胎植入率的方法
PCT/BR2011/000454 WO2012083396A1 (en)	2010-12-21	2011-12-09	Method for increasing embryo implantation rate in mother's uterus in mammals, use of an effective amount of beta - galactoside - binding lectin or derivatives thereof, beta - galactoside - binding lectin or derivatives and product.
PL11805370T PL2654897T3 (pl)	2010-12-21	2011-12-09	Sposób zwiększania tempa implantacji zarodka w macicy matki u ssaków, zastosowanie skutecznej ilości lektyny wiążącej betagalaktozyd lub jej pochodnych, lektyna wiążąca betagalaktozyd lub pochodne i produkt
RU2013133832A RU2631598C2 (ru)	2010-12-21	2011-12-09	Способ повышения частоты имплантации эмбриона в материнской матке млекопитающих, применение эффективного количества бета-галактозид-связывающего лектина или его производных, бета-галактозид-связывающий лектин или производные и продукт
ES11805370T ES2756773T3 (es)	2010-12-21	2011-12-09	Método para aumentar el índice de implantación del embrión en el útero de la madre en mamíferos, uso de una cantidad eficaz de lectina de unión al beta-galactósido o de derivados de la misma, de lectina de unión al beta-galactósido o de derivados y producto
CN201180068131.8A CN103702720B (zh)	2010-12-21	2011-12-09	用于在哺乳动物中增加母体子宫的胚胎植入率的方法
JP2013544976A JP6120374B2 (ja)	2010-12-21	2011-12-09	哺乳動物の母親の子宮における着床率を増加させる方法、有効量のベータ−ガラクトシド結合レクチンまたはその誘導体の使用、ベータ−ガラクトシド結合レクチンまたは誘導体および製品
US13/996,920 US9637533B2 (en)	2010-12-21	2011-12-09	Methods for increasing the embryo implantation rate in mammals
PT118053701T PT2654897T (pt)	2010-12-21	2011-12-09	Método para aumentar a taxa de implantação de embriões no útero da progenitora em mamíferos, utilização de uma quantidade eficaz de lectina de ligação a beta-galactósido ou seus derivados, lectina de ligação a beta-galactósido ou derivados e produto
EP19189687.7A EP3623008A1 (en)	2010-12-21	2011-12-09	Method for increasing embryo implantation rate in mother's uterus in mammals, use of an effective amount of beta-galactoside -binding lectin or derivatives thereof, beta-galactoside-binding lectin or derivatives and product
ZA2013/04626A ZA201304626B (en)	2010-12-21	2013-06-21	Method for increasing embryo implantation in mother's uterus in mammals,use of an effective amount of beta-galactoside-binding lectin or derivatives thereof,beta-galactoside-binding lectin or derivatives and product
JP2017000467A JP2017081976A (ja)	2010-12-21	2017-01-05	哺乳動物の母親の子宮における着床率を増加させる方法、有効量のベータ−ガラクトシド結合レクチンまたはその誘導体の使用、ベータ−ガラクトシド結合レクチンまたは誘導体および製品
JP2018186468A JP6673998B2 (ja)	2010-12-21	2018-10-01	哺乳動物の母親の子宮における着床率を増加させる方法、有効量のベータ−ガラクトシド結合レクチンまたはその誘導体の使用、ベータ−ガラクトシド結合レクチンまたは誘導体および製品

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
BRPI1005702A BRPI1005702B1 (pt)	2010-12-21	2010-12-21	método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto

Publications (2)

Publication Number	Publication Date
BRPI1005702A2 BRPI1005702A2 (pt)	2013-04-02
BRPI1005702B1 true BRPI1005702B1 (pt)	2020-02-04

Family

ID=45463120

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1005702A BRPI1005702B1 (pt)	2010-12-21	2010-12-21	método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto

Country Status (11)

Country	Link
US (1)	US9637533B2 (pl)
EP (2)	EP3623008A1 (pl)
JP (3)	JP6120374B2 (pl)
CN (2)	CN103702720B (pl)
BR (1)	BRPI1005702B1 (pl)
ES (1)	ES2756773T3 (pl)
PL (1)	PL2654897T3 (pl)
PT (1)	PT2654897T (pl)
RU (1)	RU2631598C2 (pl)
WO (1)	WO2012083396A1 (pl)
ZA (1)	ZA201304626B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI1005702B1 (pt)	2010-12-21	2020-02-04	Inprenha Biotecnologia E Desenvolvimento Avancado Ltda Me	método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto
JP2020514772A (ja) *	2017-01-15	2020-05-21	アレックス・ライフ・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＡｒｅｘＬｉｆｅＳｃｉｅｎｃｅｓＬｌｃ	人工授精における受精能を改善する方法
CA3155035C (en)	2019-10-29	2024-06-04	William Alan BLAIR	Apparatus to facilitate transfer of biological specimens stored at cryogenic conditions
US11817187B2 (en) *	2020-05-18	2023-11-14	TMRW Life Sciences, Inc.	Handling and tracking of biological specimens for cryogenic storage
CN111658223A (zh) *	2020-06-11	2020-09-15	上海滔华生物医药科技合伙企业（有限合伙）	一种受体牛的筛选方法
JP7610303B2 (ja)	2020-09-24	2025-01-08	ティーエムアールダブリュライフサイエンシーズ，インコーポレイテツド	極低温条件で保管された生物学的試料の移送を容易にするためのワークステーション及び装置
US12099890B2 (en)	2020-10-02	2024-09-24	TMRW Life Sciences, Inc.	Interrogation device and/or system having alignment feature(s) for wireless transponder tagged specimen containers and/or carriers
CA3200508A1 (en)	2020-12-10	2022-06-16	TMRW Life Sciences, Inc.	Specimen holder with wireless transponder for attachment to specimen collection body
EP4252009B1 (en)	2021-01-13	2025-03-05	TMRW Life Sciences, Inc.	System to pick and/or place specimen containers
EP4412453A4 (en)	2021-10-08	2025-01-22	TMRW Life Sciences, Inc.	SYSTEMS, DEVICES AND METHODS FOR TAKING AND/OR PLACING SAMPLE CONTAINERS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5869081A (en) *	1996-06-28	1999-02-09	The Population Council	Progesterone vaginal ring for treatment of infertility
WO2000032140A1 (en) *	1998-11-30	2000-06-08	Ivf Sciences Colorado, Inc.	System and sequential culture media for in vitro fertilization
WO2001065928A1 (en) *	2000-03-09	2001-09-13	Yves Chicheportiche	A method for increasing the in vitro production of cystic embryoid bodies from mammalian embryonic stem cells
RU2272630C2 (ru) *	2004-04-28	2006-03-27	ФГОУ ВПО "Курская государственная сельскохозяйственная академия им. проф. И.И. Иванова"	Способ повышения выживаемости эмбрионов у коров
US20070185014A1 (en)	2006-02-09	2007-08-09	The Schepens Eye Research Institute, Inc.	Methods and compositions for modulating conjunctival goblet cells
EP1908476A1 (en)	2006-09-28	2008-04-09	Charite-Universitätsmedizin Berlin	Galectin-2 for the treatment of inflammatory diseases of the skin
US20120178331A1 (en) *	2010-10-21	2012-07-12	Eastman Chemical Company	Nonwoven article with ribbon fibers
BRPI1005702B1 (pt)	2010-12-21	2020-02-04	Inprenha Biotecnologia E Desenvolvimento Avancado Ltda Me	método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto

2010
- 2010-12-21 BR BRPI1005702A patent/BRPI1005702B1/pt active IP Right Grant
2011
- 2011-12-09 PT PT118053701T patent/PT2654897T/pt unknown
- 2011-12-09 JP JP2013544976A patent/JP6120374B2/ja active Active
- 2011-12-09 EP EP19189687.7A patent/EP3623008A1/en not_active Withdrawn
- 2011-12-09 CN CN201180068131.8A patent/CN103702720B/zh active Active
- 2011-12-09 CN CN201811493360.4A patent/CN109966474A/zh active Pending
- 2011-12-09 US US13/996,920 patent/US9637533B2/en active Active
- 2011-12-09 ES ES11805370T patent/ES2756773T3/es active Active
- 2011-12-09 EP EP11805370.1A patent/EP2654897B1/en active Active
- 2011-12-09 PL PL11805370T patent/PL2654897T3/pl unknown
- 2011-12-09 WO PCT/BR2011/000454 patent/WO2012083396A1/en not_active Ceased
- 2011-12-09 RU RU2013133832A patent/RU2631598C2/ru active
2013
- 2013-06-21 ZA ZA2013/04626A patent/ZA201304626B/en unknown
2017
- 2017-01-05 JP JP2017000467A patent/JP2017081976A/ja not_active Withdrawn
2018
- 2018-10-01 JP JP2018186468A patent/JP6673998B2/ja active Active

Also Published As

Publication number	Publication date
JP2014500279A (ja)	2014-01-09
EP2654897A1 (en)	2013-10-30
BRPI1005702A2 (pt)	2013-04-02
CN109966474A (zh)	2019-07-05
JP6673998B2 (ja)	2020-04-01
RU2631598C2 (ru)	2017-09-25
JP2017081976A (ja)	2017-05-18
US9637533B2 (en)	2017-05-02
PT2654897T (pt)	2019-12-02
RU2013133832A (ru)	2015-01-27
CN103702720A (zh)	2014-04-02
ZA201304626B (en)	2014-09-25
JP2019023208A (ja)	2019-02-14
ES2756773T3 (es)	2020-04-27
EP3623008A1 (en)	2020-03-18
CN103702720B (zh)	2020-07-07
US20140057858A1 (en)	2014-02-27
EP2654897B1 (en)	2019-08-21
WO2012083396A1 (en)	2012-06-28
JP6120374B2 (ja)	2017-04-26
PL2654897T3 (pl)	2020-05-18

Legal Events

Date	Code	Title	Description
2013-04-02	B03A	Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B07G	Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]	Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-16	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-12-17	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-02-04	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/12/2010, OBSERVADAS AS CONDICOES LEGAIS.

Publication	Publication Date	Title
BRPI1005702B1 (pt)	2020-02-04	método para aumentar a taxa de implantação de embriões no útero materno em mamíferos, uso de uma quantidade eficaz de uma lectina ligante de beta-galactosídeo ou derivados da mesma e produto
Bromfield	2016	A role for seminal plasma in modulating pregnancy outcomes in domestic species
Geary et al.	2013	Triennial Reproduction Symposium: influence of follicular characteristics at ovulation on early embryonic survival
Peña et al.	2017	Revisiting summer infertility in the pig: could heat stress-induced sperm DNA damage negatively affect early embryo development?
Jewgenow et al.	2014	Reproduction and advances in reproductive studies in carnivores
Davachi et al.	2017	The effect of conspecific ampulla oviductal epithelial cells during in vitro maturation on oocyte developmental competence and maturation-promoting factor (MPF) activity in sheep
Nadaf et al.	2022	Comparative ejaculatory response, fresh and frozen semen quality and fertility to artificial vagina vs electroejaculation method of semen collection in mithun (Bos frontalis) bulls
Makarevich et al.	2016	Quality of preimplantation embryos recovered in vivo from dairy cows in relation to their body condition
Dhangada et al.	2024	Innovative Reproductive Technology in Animal Breeding: A Review
McGetrick et al.	2014	Improving bovine semen diluents: insights from the male and female reproductive tracts, and the potential relevance of cervical mucins
Kouamo et al.	2014	An overview of sex selection at conception in mammals.
Zobel et al.	2011	Influence of the semen deposition site on the calves’ sex ratio in Simmental dairy cattle
HK40010307A (en)	2020-07-03	Method for increasing embryo implantation rate in mother's uterus in mammals
Morani et al.	2021	Improvement of beef cattle cow’s pregnancy rate using an effective dose of Galectin-1
Harrison	2021	Nutritional effects on scrotal circumference, motility and morphology of spermatozoa and cytokine concentrations within seminal plasma of beef cattle
Haimon et al.	2022	1 Culture with choline chloride programs development of the in vitro-produced bovine embryo to increase postnatal bodyweight, growth rate, and testes size
Aubuchon	2022	Utilization of sex-sorted semen in beef cattle
SD	2023	Embryo Production and Development from Superovulated Donors in Double-Muscled Cattle and Their Crosses.
Mohlomi	2015	Evaluation of cryopreserved ram semen following fertilization in vitro
Santos et al.	2026	Heterospermic semen: Implications for managing bull-to-bull variation in fertility
Arnal et al.	2019	Embryo-induced alterations in the endometrial transcriptome of prepubertal bovine heifers
Almeida et al.	2018	Prostaglandin F2α as an inducer of ovulation in Fixed Timed Artificial Insemiantion in Zebu cows
Martinez et al.	2025	Impact of Seminal Plasma on the Embryonic Development and Uterine Environment in Pigs
Hussain	2018	Baqer Ja’fer. Hassan
Paccola et al.	2019	Effect of Intrauterine and breast-feeding nicotine exposure on oocytes quality and reproductive capacity of adult rats